Journal of Rehabilitation Medicine · 2022 · 11 citations · 33 references
MedicineNeurologyPharmacotherapyNeurorehabilitationPhysical TherapyRehabilitationNeurological RehabilitationPhysical RehabilitationSpasticity ManagementSpasticity PharmacotherapyStrokeStroke PharmacotherapyFunctional Recovery MetricsLong-term Disability BenefitsLong-term Neurologic OutcomesOutcome Measurement In SpasticityPost-stroke RecoveryPost-stroke RehabilitationQuality-adjusted Life Year ModelingStroke-related Mobility Impairment
Objective: Stroke is associated with a high risk of death and cardiovascular events. Rehabilitation therapy is critical for functional recovery, to reduce hospital readmissions, all-cause and cardiovascular mortality, and stroke recurrence (long-term outcomes). Post-stroke spasticity may prevent effective recovery by restricting mobility. AbobotulinumtoxinA is an adjunctive therapy to physical therapy for post-stroke spasticity, but its long-term effects are unknown. The objective was to model the long-term clinical and economic outcomes of abobotulinumtoxinA for post-stroke spasticity.Methods: Effects of abobotulinumtoxinA on treating post-stroke spasticity and evidence linking functional outcomes with long-term outcomes were collected in a focused literature review. A model was developed to estimate health benefits on long-term outcomes, direct medical costs, life- and qualityadjusted life-years for abobotulinumtoxinA injections plus rehabilitation therapy compared with rehabilitation therapy alone, from a UK perspective over a 10-year time-period.Results: AbobotulinumtoxinA + rehabilitation therapy led to a risk reduction of 8.8% for all-cause mortality, and an increase of 13% in life-years and 59% in quality-adjusted life-years compared with rehabilitation therapy alone. AbobotulinumtoxinA + rehabilitation therapy was considered cost-effective compared with rehabilitation therapy alone (incremental cost-effectiveness ratio: £24,602).Conclusion: AbobotulinumtoxinA + rehabilitation therapy may improve long-term outcomes, including post-stroke survival, while being cost-effective for the treatment of post-stroke spasticity. LAY ABSTRACTHere we developed a model to explore and compare the long-term benefits and overall costs of two interventions for the treatment of post-stroke spasticity (PSS): abobotulinumtoxinA injections plus rehabilitation therapy (aboBoNT-A+RT) vs. RT alone. Stroke survivors are known to be at a higher risk of recurrent stroke and death, and more than 25% are affected by spasticity. PSS significantly reduces patients’ mobility, physical functioning, and subsequently their ability to recover after a stroke. AboBoNT-A+RT is an effective treatment for spasticity. This model is the first to highlight that combining aboBoNT-A injections with RT could improve the overall survival of stroke survivors with spasticity by 8.8% and their overall quality of life, while being considered good value for money by UK payers.
33
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
Walter N. Kernan, Bruce Ovbiagele, Henry R. Black et al. · Stroke · 2014 · 5.2K citations
Hatem A Wafa, Charles Wolfe, Eva Emmett et al. · Stroke · 2020 · 817 citations · Full text
Action Plan for Stroke in Europe 2018–2030
Bo Norrving, Jon Barrick, Antoni Dávalos et al. · European Stroke Journal · 2018 · 603 citations · Full text
Medicine, Health Policy, Neurology +17
Treatment of spasticity with botulinum toxin: A double‐blind study
Barry Snow, Joseph Tsui, Mohit Bhatt et al. · Annals of Neurology · 1990 · 416 citations